Sirnaomics Ltd. has been successfully listed on the Mainboard of HKSE on 30 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application.
Sirnaomics is an RNA therapeutics biopharmaceutical company. Founded in 2007 in the U.S., the company is the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic. With research and development centers in both China and the U.S., the company delivers pre-clinical and clinical stage products and focuses on the discovery and development of innovative drugs.
Sirnaomics’ core product STP705 demonstrated efficacy and safety in an oncology Phase I/II clinical trial for non-melanoma skin cancer. STP705 was further advanced in a Phase IIb clinical trial for squamous cell carcinoma in situ (isSCC), a Phase II clinical trial for treatment of skin basal cell carcinoma (BCC), a Phase II clinical trial for treatment of keloid and a Phase I/II clinical trial for treatment of hypertrophic scar (HTS). Sirnaomics has initiated a Phase I clinical trial using STP705 for treatment of liver cancer (basket) through a local injection based on an independent IND approval from US FDA.
In addition, Sirnaomics will further optimize its drug delivery technology platforms and strengthen its capabilities to manufacture its products in large scale to promote the rapid growth of different clinical stage product lines they have currently and in the future.